The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...
Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic ...
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...
A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.
The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...
ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the ...
Researchers at the Medical College of Georgia found that androgen deprivation therapy (ADT) for prostate cancer may increase Alzheimer’s risk by damaging the blood-brain barrier and promoting brain ...
A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...
1d
German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug ...
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback